X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1571) 1571
Publication (98) 98
Book Review (37) 37
Newsletter (35) 35
Newspaper Article (4) 4
Data Set (3) 3
Book Chapter (2) 2
Dissertation (2) 2
Book / eBook (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fluvoxamine (1111) 1111
humans (980) 980
male (889) 889
pharmacology & pharmacy (708) 708
psychiatry (661) 661
female (617) 617
adult (579) 579
middle aged (380) 380
animals (370) 370
neurosciences (359) 359
fluoxetine (356) 356
index medicus (341) 341
fluvoxamine - pharmacology (301) 301
fluvoxamine - therapeutic use (289) 289
serotonin uptake inhibitors - therapeutic use (261) 261
fluvoxamine - administration & dosage (260) 260
antidepressants (258) 258
dose-response relationship, drug (258) 258
treatment outcome (254) 254
clinical neurology (236) 236
paroxetine (236) 236
rats (235) 235
serotonin uptake inhibitors - pharmacology (226) 226
depression (221) 221
double-blind (213) 213
serotonin (209) 209
serotonin reuptake inhibitors (198) 198
drug interactions (195) 195
serotonin uptake inhibitors - administration & dosage (193) 193
sertraline (187) 187
double-blind method (186) 186
obsessive-compulsive disorder (176) 176
aged (172) 172
adolescent (164) 164
depressive disorder - drug therapy (159) 159
fluvoxamine - adverse effects (159) 159
drug administration schedule (158) 158
serotonin uptake inhibitors - adverse effects (150) 150
pharmacokinetics (148) 148
obsessive-compulsive disorder - drug therapy (133) 133
psychiatric status rating scales (133) 133
drug therapy, combination (128) 128
serotonin uptake inhibitors (128) 128
drug therapy (126) 126
mice (120) 120
metabolism (119) 119
major depression (118) 118
antidepressive agents - therapeutic use (115) 115
citalopram (115) 115
efficacy (115) 115
time factors (102) 102
fluvoxamine - pharmacokinetics (97) 97
placebo (96) 96
analysis (91) 91
schizophrenia (90) 90
child (89) 89
antidepressive agents, second-generation - therapeutic use (88) 88
clomipramine (87) 87
depressive disorder, major - drug therapy (86) 86
anxiety (84) 84
rats, wistar (83) 83
rat (81) 81
dosage and administration (80) 80
research (80) 80
in-vitro (76) 76
pharmacotherapy (76) 76
serotonin - metabolism (76) 76
rats, sprague-dawley (73) 73
area under curve (72) 72
brain (72) 72
imipramine (72) 72
antidepressive agents - pharmacology (71) 71
drugs (71) 71
ssri (71) 71
pharmacology (70) 70
psychology, clinical (70) 70
antidepressant (69) 69
administration, oral (67) 67
care and treatment (67) 67
clozapine (67) 67
depressive disorder - psychology (67) 67
fluvoxamine - blood (67) 67
medicine & public health (67) 67
pharmacology/toxicology (67) 67
antidepressive agents, second-generation - adverse effects (66) 66
psychology (66) 66
desipramine (64) 64
paroxetine - pharmacology (64) 64
antipsychotic agents - therapeutic use (62) 62
obsessive-compulsive disorder - psychology (62) 62
severity of illness index (62) 62
antidepressive agents - administration & dosage (61) 61
fluoxetine - pharmacology (60) 60
toxicology (60) 60
schizophrenia - drug therapy (59) 59
genotype (58) 58
depression - drug therapy (57) 57
fluoxetine - therapeutic use (57) 57
major depressive disorder (57) 57
paroxetine - therapeutic use (57) 57
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1552) 1552
Japanese (24) 24
French (12) 12
German (8) 8
Russian (6) 6
Polish (5) 5
Persian (3) 3
Dutch (2) 2
Turkish (2) 2
Danish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
CMAJ, ISSN 0820-3946, 11/2011, Volume 183, Issue 16, pp. 1835 - 1843
Background: Patients prescribed antiplatelet treatment to prevent recurrent acute myocardial infarction are often also given a selective serotonin reuptake... 
DEPRESSION | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | ANTIDEPRESSANTS | CLOPIDOGREL | EVENTS | PROGNOSIS | DRUGS | ELDERLY-PATIENTS | ASPIRIN | Age Factors | Anemia - epidemiology | Angioplasty | Humans | Middle Aged | Citalopram - adverse effects | Male | Risk | Secondary Prevention | Sertraline - adverse effects | Peptic Ulcer - epidemiology | Adrenal Cortex Hormones - therapeutic use | Renal Insufficiency - epidemiology | Aspirin - administration & dosage | Paroxetine - adverse effects | Paroxetine - administration & dosage | Fluvoxamine - administration & dosage | Canada - epidemiology | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Retrospective Studies | Drug Therapy, Combination | Heart Failure - epidemiology | Fluoxetine - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Hypoglycemic Agents - therapeutic use | Hemorrhage - epidemiology | Risk Factors | Serotonin Uptake Inhibitors - adverse effects | Anticoagulants - therapeutic use | Antihypertensive Agents - therapeutic use | Fluvoxamine - adverse effects | Ticlopidine - analogs & derivatives | Citalopram - administration & dosage | Sertraline - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Sex Factors | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Neoplasms - epidemiology | Cohort Studies | Aggregation | Complications and side effects | Blood platelets | Patient outcomes | Serotonin uptake inhibitors | Dosage and administration | Drug therapy | Hemorrhage | Heart attack | Risk factors | Studies | Side effects | Heart attacks | Inhibitor drugs | Research
Journal Article
Journal Article
Molecular Psychiatry, ISSN 1359-4184, 07/2006, Volume 11, Issue 7, pp. 622 - 632
As many as half of obsessive-compulsive disorder ( OCD) patients treated with an adequate trial of serotonin reuptake inhibitors ( SRIs) fail to fully respond... 
Antipsychotic agents | Systematic review | Tics | Obsessive-compulsive disorder | Meta-analysis | UNITED-STATES | HALOPERIDOL | PSYCHIATRY | obsessive-compulsive disorder | BIOCHEMISTRY & MOLECULAR BIOLOGY | FLUVOXAMINE | meta-analysis | FOLLOW-UP | antipsychotic agents | systematic review | NEUROSCIENCES | TOURETTE-SYNDROME | SEROTONIN REUPTAKE INHIBITORS | tics | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | RISPERIDONE AUGMENTATION | EPIDEMIOLOGY | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Haloperidol - administration & dosage | Depressive Disorder - drug therapy | Obsessive-Compulsive Disorder - complications | Dibenzothiazepines - therapeutic use | Risperidone - therapeutic use | Antipsychotic Agents - therapeutic use | Adult | Tic Disorders - drug therapy | Drug Therapy, Combination | Drug Resistance | Tic Disorders - complications | Basal Ganglia Diseases - chemically induced | Patient Dropouts - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Double-Blind Method | Comorbidity | Quetiapine Fumarate | Risperidone - administration & dosage | Serotonin Uptake Inhibitors - therapeutic use | Haloperidol - therapeutic use | Treatment Outcome | Dibenzothiazepines - administration & dosage | Antipsychotic Agents - administration & dosage | Depressive Disorder - complications | Obsessive-Compulsive Disorder - drug therapy | Serotonin Uptake Inhibitors - administration & dosage | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - therapeutic use
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1004 - 1011
Journal Article
Journal of Clinical Psychiatry, ISSN 0160-6689, 06/2009, Volume 70, Issue 6, pp. 863 - 868
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 01/2018, Volume 81, Issue 1, pp. 73 - 80
PURPOSE: Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1-3, FGFR 1-3, and PDGFR. This study was performed to... 
TKI258 | Dovitinib | Fluvoxamine | Drug–drug interaction | CYP1A2 | Fluvoxamine CYP1A2 | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | PHASE-II | OPEN-LABEL | SORAFENIB | CANCER | FLUOXETINE | FGFR | RENAL-CELL CARCINOMA | TRIAL | METABOLISM | ONCOLOGY | VEGFR | PHARMACOLOGY & PHARMACY | Drug-drug interaction | Area Under Curve | Humans | Middle Aged | Half-Life | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Drug Interactions | Fluvoxamine - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Quinolones - pharmacokinetics | Quinolones - therapeutic use | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP1A2 Inhibitors - adverse effects | Benzimidazoles - therapeutic use | Cytochrome P-450 CYP1A2 Inhibitors - therapeutic use | Fluvoxamine - therapeutic use | Drug Administration Schedule | Benzimidazoles - pharmacokinetics | Fluvoxamine - pharmacology | Neoplasms - drug therapy | Maximum Tolerated Dose | Quinolones - administration & dosage | Cytochrome P-450 CYP1A2 Inhibitors - pharmacology | Cytochrome P-450 CYP1A2 Inhibitors - administration & dosage | Aged | Tyrosine | Complications and side effects | Care and treatment | Drug interactions | Cytochrome P-450 | Pharmaceutical industry | Vascular endothelial growth factor | Tumors | Toxicity | Cytochrome P450 | Breast cancer | Pharmacology | CYP1A2 protein | Patients | Coefficient of variation | Steady state | Vascular endothelial growth factor receptors | Confidence intervals | Inhibitors | Drug interaction | Solid tumors | Pharmacokinetics | Drug dosages | Protein-tyrosine kinase | Smoking | Fibroblast growth factor receptors | Index Medicus
Journal Article
Journal Article